196 related articles for article (PubMed ID: 36781622)
1. Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review.
Damato A; Ghidini M; Dottorini L; Tomasello G; Iaculli A; Ghidini A; Luciani A; Petrelli F
Curr Oncol Rep; 2023 Apr; 25(4):341-352. PubMed ID: 36781622
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
3. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
4. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
5. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
6. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo.
Paccagnella A; Orlando A; Marchiori C; Zorat PL; Cavaniglia G; Sileni VC; Jirillo A; Tomio L; Fila G; Fede A
J Natl Cancer Inst; 1994 Feb; 86(4):265-72. PubMed ID: 8158680
[TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
Feng QY; Wei Y; Chen JW; Chang WJ; Ye LC; Zhu DX; Xu JM
World J Gastroenterol; 2014 Apr; 20(15):4263-75. PubMed ID: 24764664
[TBL] [Abstract][Full Text] [Related]
9. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.
Adam R; De Gramont A; Figueras J; Guthrie A; Kokudo N; Kunstlinger F; Loyer E; Poston G; Rougier P; Rubbia-Brandt L; Sobrero A; Tabernero J; Teh C; Van Cutsem E;
Oncologist; 2012; 17(10):1225-39. PubMed ID: 22962059
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32).
Kusano M; Aoyama T; Okabayashi K; Hirata K; Tsuji Y; Nakamori S; Asahara T; Ohashi Y; Yoshikawa T; Sakamoto J; Oba K; Saji S
J Cancer Res Ther; 2018 Sep; 14(Supplement):S761-S766. PubMed ID: 30249900
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery.
AlGizawy SM; Essa HH; Ahmed BM
Oncologist; 2015 Jul; 20(7):752-7. PubMed ID: 26040621
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy in resectable or potentially resectable colon cancer with liver metastases.
Samoon Z; Naher SK; Sjoquist KM; Zalcberg J
Expert Opin Pharmacother; 2022 Apr; 23(6):663-672. PubMed ID: 35196945
[TBL] [Abstract][Full Text] [Related]
13. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
14. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
15. Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
Tsai HL; Chen YT; Yeh YS; Huang CW; Ma CJ; Wang JY
Pathol Oncol Res; 2019 Jul; 25(3):905-913. PubMed ID: 29299827
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
18. [Combined treatment of inoperable liver metastases from colorectal cancer].
Milandri C; Calzolari F; Giampalma E; Vagliasindi A; Bertagni A; Ridolfi L; Passardi A; Ridolfi R; Golfieri R; Verdecchia GM
Tumori; 2003; 89(4 Suppl):112-4. PubMed ID: 12903565
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
Ychou M; Rivoire M; Thezenas S; Guimbaud R; Ghiringhelli F; Mercier-Blas A; Mineur L; Francois E; Khemissa F; Chauvenet M; Kianmanesh R; Fonck M; Houyau P; Aparicio T; Galais MP; Audemar F; Assenat E; Lopez-Crapez E; Jouffroy C; Adenis A; Adam R; Bouché O
Br J Cancer; 2022 May; 126(9):1264-1270. PubMed ID: 34992255
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
